Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Brain Retrieve available abstracts of 96 articles: HTML format

Single Articles

May 2024
1. JAMET Z, Mergaux C, Meras M, Bouchet D, et al
   NMDA receptor autoantibodies primarily impair the extrasynaptic compartment.
   Brain. 2024 May 17:awae163. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2024
2. HUANG J, Tengvall K, Bomfim Lima I, Hedstrom AK, et al
   Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
   Brain. 2024 Apr 17:awae110. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. ARELLANO G, Loda E, Chen Y, Neef T, et al
   Interferon-gamma controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.
   Brain. 2024;147:1344-1361.
   PubMed     Abstract available
   
   
   March 2024
4. MAINERO C, Miscioscia A, Treaba CA
   Cortical remyelination in multiple sclerosis: a target for disease monitoring and intervention.
   Brain. 2024 Mar 27:awae083. doi: 10.1093.
   PubMed    
   
   
   January 2024
5. HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
   Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
   Brain. 2024 Jan 30:awae030. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. LAZZAROTTO A, Hamzaoui M, Tonietto M, Dubessy AL, et al
   Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
   Brain. 2024 Jan 24:awae024. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. BAGNATO F, Sati P, Hemond CC, Elliott C, et al
   Imaging chronic active lesions in multiple sclerosis: a consensus statement.
   Brain. 2024 Jan 16:awae013. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. SCHWAB N
   Transcriptomics reveals CSF cellular composition in multiple sclerosis but detects no viral RNA.
   Brain. 2024 Jan 5:awae006. doi: 10.1093.
   PubMed    
   
   
   
9. QIN C, Chen M, Dong MH, Yang S, et al
   Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
   Brain. 2024;147:163-176.
   PubMed     Abstract available
   
   
   
10. JAMANN H, Desu HL, Cui QL, Halaweh A, et al
    ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.
    Brain. 2024;147:147-162.
    PubMed     Abstract available
    
    
    December 2023
11. MARZIALI LN, Hwang Y, Palmisano M, Cuenda A, et al
    p38gamma MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.
    Brain. 2023 Dec 21:awad421. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. CALLEGARI I, Oechtering J, Schneider M, Perriot S, et al
    Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
    Brain. 2023 Dec 20:awad424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. CREE BAC
    Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?
    Brain. 2023 Dec 18:awad418. doi: 10.1093.
    PubMed    
    
    
    
14. CLEAVER J, Jeffery K, Klenerman P, Lim M, et al
    The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity.
    Brain. 2023 Dec 13:awad419. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. BUTZKUEVEN H, Ponsonby AL, Stein MS, Lucas RM, et al
    Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
    Brain. 2023 Dec 12:awad409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. BAN M, Bredikhin D, Huang Y, Bonder MJ, et al
    Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.
    Brain. 2023 Dec 1:awad404. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
17. KEDDIE S, Smyth D, Keh RYS, Chou MKL, et al
    Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
    Brain. 2023;146:4562-4573.
    PubMed     Abstract available
    
    
    October 2023
18. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
    Brain. 2023 Oct 31:awad374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. BERNARD HEALEY SA, Giovannoni G, Noyce A, Dobson R, et al
    Impact of multiple sclerosis risk alleles on the plasma proteome.
    Brain. 2023 Oct 18:awad363. doi: 10.1093.
    PubMed    
    
    
    
20. ALLEN NM, O'Rahelly M, Eymard B, Chouchane M, et al
    The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD).
    Brain. 2023;146:4233-4246.
    PubMed     Abstract available
    
    
    September 2023
21. MATSUMOTO Y, Kaneko K, Takahashi T, Takai Y, et al
    Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Brain. 2023;146:3938-3948.
    PubMed     Abstract available
    
    
    August 2023
22. KEDDIE S, Smyth D, Keh RYS, Wieske L, et al
    Reply: Peripherin is a biomarker of axonal damage in Guillain Barre syndrome: a pathophysiological annotation.
    Brain. 2023 Aug 30:awad276. doi: 10.1093.
    PubMed    
    
    
    
23. FLEISCHER V, Gonzalez-Escamilla G, Pareto D, Rovira A, et al
    Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Brain. 2023 Aug 29:awad288. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. LEYPOLDT F, Wandinger KP
    Post-herpes simplex virus encephalitis autoimmunity: more the rule than the exception.
    Brain. 2023 Aug 28:awad290. doi: 10.1093.
    PubMed    
    
    
    
25. BERCIANO J
    Peripherin is a biomarker of axonal damage in Guillain Barre syndrome: a pathophysiological annotation.
    Brain. 2023 Aug 17:awad277. doi: 10.1093.
    PubMed    
    
    
    
26. LEBRUN-FRENAY C, Okuda DT, Siva A, Landes-Chateau C, et al
    The radiologically isolated syndrome: revised diagnostic criteria.
    Brain. 2023;146:3431-3443.
    PubMed     Abstract available
    
    
    June 2023
27. SHARMIN S, Roos I, Simpson-Yap S, Malpas C, et al
    The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
    Brain. 2023 Jun 27:awad218. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. HENRIET E, Martin EM, Jubin P, Langui D, et al
    Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies.
    Brain. 2023;146:2453-2463.
    PubMed     Abstract available
    
    
    
29. CORTESE R, Battaglini M, Prados F, Bianchi A, et al
    Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
    Brain. 2023;146:2489-2501.
    PubMed     Abstract available
    
    
    April 2023
30. CHARABATI M, Zandee S, Fournier AP, Tastet O, et al
    MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.
    Brain. 2023;146:1483-1495.
    PubMed     Abstract available
    
    
    
31. GUO Y, Lennon VA
    A distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis?
    Brain. 2023 Apr 3:awad107. doi: 10.1093.
    PubMed    
    
    
    March 2023
32. LIN J, Zhou J, Xu Y
    Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.
    Brain. 2023 Mar 2:awad070. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
33. WONG JK, Lin J, Kung NJ, Tse AL, et al
    Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic.
    Brain. 2023 Feb 3:awad031. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2022
34. NIJ BIJVANK JA, Hof SN, Prouskas SE, Schoonheim MM, et al
    A novel eye-movement impairment in multiple sclerosis indicating wide-spread cortical damage.
    Brain. 2022 Dec 20:awac474. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. JAMES BATES RE, Browne E, Schalks R, Jacobs H, et al
    Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration.
    Brain. 2022;145:4287-4307.
    PubMed     Abstract available
    
    
    
36. PISA M, Pansieri J, Yee S, Ruiz J, et al
    Anterior optic pathway pathology in CNS demyelinating diseases.
    Brain. 2022;145:4308-4319.
    PubMed     Abstract available
    
    
    November 2022
37. JOKUBAITIS VG, Campagna MP, Ibrahim O, Stankovich J, et al
    Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.
    Brain. 2022 Nov 30:awac449. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. GAUTHIER SA
    Location, location, location: myelin repair and proximity to ventricular CSF in multiple sclerosis.
    Brain. 2022 Nov 30:awac448. doi: 10.1093.
    PubMed    
    
    
    
39. ARRAMBIDE G, Espejo C, Carbonell-Mirabent P, Dieli-Crimi R, et al
    The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria.
    Brain. 2022;145:3931-3942.
    PubMed     Abstract available
    
    
    
40. CORDANO C, Sin JH, Timmons G, Yiu HH, et al
    Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy.
    Brain. 2022;145:3943-3952.
    PubMed     Abstract available
    
    
    
41. LIN X, Yang Y, Gresle M, Cuellar-Partida G, et al
    Novel plasma and brain proteins that are implicated in multiple sclerosis.
    Brain. 2022 Nov 8. pii: 6809197. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. GARTON T, Gill AJ, Calabresi PA
    Distinct mechanisms of oligodendrocyte injury inform therapeutic interventions in multiple sclerosis.
    Brain. 2022 Nov 3. pii: 6794531. doi: 10.1093.
    PubMed    
    
    
    
43. ROSTGAARD K, Nielsen NM, Melbye M, Frisch M, et al
    Siblings reduce multiple sclerosis risk by preventing delayed primary Epstein-Barr virus infection.
    Brain. 2022 Nov 1. pii: 6783238. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2022
44. VAN STEENHOVEN RW, Titulaer MJ
    Seronegative autoimmune encephalitis: exploring the unknown.
    Brain. 2022 Sep 16. pii: 6701799. doi: 10.1093.
    PubMed    
    
    
    
45. TONIETTO M, Poirion E, Lazzarotto A, Ricigliano V, et al
    Periventricular remyelination failure in multiple sclerosis: a substrate for neurodegeneration.
    Brain. 2022 Sep 13. pii: 6696508. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. TEPAVCEVIC V, Lubetzki C
    Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
    Brain. 2022 Sep 12. pii: 6696052. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2022
47. AL-DIWANI A, Theorell J, Damato V, Bull J, et al
    Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis.
    Brain. 2022;145:2742-2754.
    PubMed     Abstract available
    
    
    July 2022
48. GOVERT F, Abrante L, Becktepe J, Balint B, et al
    Distinct movement disorders in contactin-associated-protein-like-2 antibody associated autoimmune encephalitis.
    Brain. 2022 Jul 25. pii: 6649472. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. BHARGAVA P, Hartung HP, Calabresi PA
    Contribution of B cells to cortical damage in multiple sclerosis.
    Brain. 2022 Jul 1. pii: 6623951. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
50. DADAR M, Mahmoud S, Narayanan S, Collins DL, et al
    Diffusely abnormal white matter converts to T2 lesion volume in the absence of MRI-detectable acute inflammation.
    Brain. 2022;145:2008-2017.
    PubMed     Abstract available
    
    
    
51. RUCK T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, et al
    Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
    Brain. 2022;145:1711-1725.
    PubMed     Abstract available
    
    
    
52. BRADL M
    From astrocyte destruction to axon injury: watching lesion evolution in experimental neuromyelitis optica.
    Brain. 2022;145:1581-1583.
    PubMed    
    
    
    
53. HERWERTH M, Kenet S, Schifferer M, Winkler A, et al
    A new form of axonal pathology in a spinal model of neuromyelitis optica.
    Brain. 2022;145:1726-1742.
    PubMed     Abstract available
    
    
    
54. ADRICHEM ME, Lucke IM, Vrancken AFJE, Goedee HS, et al
    Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2022;145:1641-1652.
    PubMed     Abstract available
    
    
    
55. COLES A
    Campath, clones and the cause of autoimmunity.
    Brain. 2022;145:1579-1580.
    PubMed    
    
    
    
56. MADSEN MAJ, Wiggermann V, Marques MFM, Lundell H, et al
    Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study.
    Brain. 2022 Jun 2. pii: 6599027. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2022
57. GUO Y, Lennon VA, Parisi JE, Popescu B, et al
    Spectrum of sublytic astrocytopathy in neuromyelitis optica.
    Brain. 2022;145:1379-1390.
    PubMed     Abstract available
    
    
    
58. BERNARD-VALNET R, Frieser D, Nguyen XH, Khajavi L, et al
    Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy.
    Brain. 2022 May 13. pii: 6581499. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. EISSMAN JM, Dumitrescu L, Mahoney ER, Smith AN, et al
    Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.
    Brain. 2022 May 13. pii: 6585174. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. LEE WJ, Lee HS, Kim DY, Lee HS, et al
    Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes.
    Brain. 2022 May 5. pii: 6580901. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
61. CORNBLATH DR, van Doorn PA, Hartung HP, Merkies ISJ, et al
    Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
    Brain. 2022;145:887-896.
    PubMed     Abstract available
    
    
    March 2022
62. STRIPPEL C, Herrera-Rivero M, Wendorff M, Tietz AK, et al
    A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies.
    Brain. 2022 Mar 28. pii: 6555060. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. PORTACCIO E, Bellinvia A, Fonderico M, Pasto L, et al
    Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Brain. 2022 Mar 24. pii: 6553893. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. SHAMS H, Shao X, Santaniello A, Kirkish G, et al
    Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.
    Brain. 2022 Mar 7. pii: 6542574. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2022
65. PERNIN F, Luo J, Cui QL, Blain M, et al
    Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis.
    Brain. 2022 Feb 24. pii: 6535861. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. KEH RYS, Scanlon S, Datta-Nemdharry P, Donegan K, et al
    COVID-19 vaccination and Guillain-Barre syndrome: analyses using the National Immunoglobulin Database.
    Brain. 2022 Feb 18. pii: 6532037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. LUBLIN FD, Haring DA, Ganjgahi H, Ocampo A, et al
    How patients with multiple sclerosis acquire disability.
    Brain. 2022 Feb 1. pii: 6519354. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
68. NISHIHARA H, Perriot S, Gastfriend BD, Steinfort M, et al
    Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis.
    Brain. 2022 Jan 27. pii: 6516047. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
69. GREEN AJ
    Socioeconomic disadvantage in multiple sclerosis: does inequality act on the substrate for disability?
    Brain. 2021 Dec 20. pii: 6470562. doi: 10.1093.
    PubMed    
    
    
    
70. CAROTENUTO A, Cacciaguerra L, Pagani E, Preziosa P, et al
    Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability.
    Brain. 2021 Dec 17. pii: 6469024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. NTRANOS A, Park HJ, Wentling M, Tolstikov V, et al
    Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.
    Brain. 2021 Dec 11. pii: 6459638. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
72. LIEBMANN M, Korn L, Janoschka C, Albrecht S, et al
    Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.
    Brain. 2021;144:3126-3141.
    PubMed     Abstract available
    
    
    
73. ZIEGLER D, Bonhof GJ, Strom A, Strassburger K, et al
    Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years.
    Brain. 2021;144:3251-3263.
    PubMed     Abstract available
    
    
    October 2021
74. VASILEIOU ES, Filippatou AG, Pimentel Maldonado D, Kalaitzidis G, et al
    Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis.
    Brain. 2021 Oct 29. pii: 6414110. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. RODGERS J, Friede T, Vonberg FW, Constantinescu CS, et al
    The impact of smoking cessation on multiple sclerosis disease progression.
    Brain. 2021 Oct 8. pii: 6384574. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
76. LUIJTEN LWG, Leonhard SE, van der Eijk AA, Doets AY, et al
    Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study.
    Brain. 2021 Sep 23. pii: 6373760. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. TAKAI Y, Misu T, Suzuki H, Takahashi T, et al
    Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
    Brain. 2021;144:2401-2415.
    PubMed     Abstract available
    
    
    August 2021
78. NAUGHTON M, de la Fuente AG
    Autoantibodies and microglia: boon or bane?
    Brain. 2021 Aug 11. pii: 6348165. doi: 10.1093.
    PubMed    
    
    
    July 2021
79. BENALLEGUE N, Kebir H, Kapoor R, Crockett A, et al
    The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation.
    Brain. 2021;144:1670-1683.
    PubMed     Abstract available
    
    
    
80. JENSEN TS, Karlsson P, Gylfadottir SS, Andersen ST, et al
    Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management.
    Brain. 2021;144:1632-1645.
    PubMed     Abstract available
    
    
    
81. MITSDOERFFER M, Di Liberto G, Dotsch S, Sie C, et al
    Corrigendum to: Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity.
    Brain. 2021 Jul 14. pii: 6321151. doi: 10.1093.
    PubMed    
    
    
    June 2021
82. BITTNER S, Oh J, Havrdova EK, Tintore M, et al
    The potential of serum neurofilament as biomarker for multiple sclerosis.
    Brain. 2021 Jun 28. pii: 6310737. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. COLLORONE S, Prados F, Kanber B, Cawley NM, et al
    Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event.
    Brain. 2021;144:1409-1421.
    PubMed     Abstract available
    
    
    
84. HAIDER L, Prados F, Chung K, Goodkin O, et al
    Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
    Brain. 2021;144:1384-1395.
    PubMed     Abstract available
    
    
    
85. PELLERIN K, Rubino SJ, Burns JC, Smith BA, et al
    MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.
    Brain. 2021 Jun 18. pii: 6305830. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
86. GRANZIERA C, Wuerfel J, Barkhof F, Calabrese M, et al
    Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.
    Brain. 2021 May 10. pii: 6273092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. VAN DOORN PA, Hadden RDM, Van den Bergh PYK
    Elucidating autoimmune nodopathies and the CIDP spectrum.
    Brain. 2021;144:1043-1045.
    PubMed    
    
    
    
88. PASCUAL-GONI E, Fehmi J, Lleixa C, Martin-Aguilar L, et al
    Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
    Brain. 2021;144:1183-1196.
    PubMed     Abstract available
    
    
    April 2021
89. FLECK AK, Hucke S, Teipel F, Eschborn M, et al
    Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity.
    Brain. 2021 Apr 26. pii: 6252379. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. GHORBANI S, Yong VW
    The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis.
    Brain. 2021 Apr 23. pii: 6247173. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. PARDINI M, Brown JWL, Magliozzi R, Reynolds R, et al
    Surface-in pathology in multiple sclerosis: a new view on pathogenesis?
    Brain. 2021 Apr 20. pii: 6238675. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. PISA M, Croese T, Dalla Costa G, Guerrieri S, et al
    Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes.
    Brain. 2021 Apr 8. pii: 6215108. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. LUCCHESE G, Floel A
    Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry.
    Brain. 2021 Apr 3. pii: 6209729. doi: 10.1093.
    PubMed    
    
    
    
94. LUNN MP, Carr AC, Keddie S, Pakpoor J, et al
    Reply: Guillain-Barre syndrome, SARS-CoV-2 and molecular mimicry and Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome and Unclear association between COVID-19 and Guillain-Barre syndrome and Currently avai
    Brain. 2021 Apr 3. pii: 6209732. doi: 10.1093.
    PubMed    
    
    
    
95. FOSCHI M, D'Anna L, Abdelhak A, Mayer B, et al
    Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209733. doi: 10.1093.
    PubMed    
    
    
    
96. GONZALEZ DEL CASTILLO J, Porta-Etessam J, Miro O
    Currently available data regarding the potential association between COVID-19 and Guillain-Barre syndrome.
    Brain. 2021 Apr 3. pii: 6209731. doi: 10.1093.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.